FDA advisors considering Tysabri

Share this article:
An advisory panel is set to make recommendations to the FDA this week about whether to allow multiple sclerosis drug Tysabri (natalizumab) back on the market. The advisory committee, which starts meeting Tuesday and will issue recommendations Wednesday, will discuss the drug’s risk-benefit profile and whether Tysabri should be available for at least some patients. Tysabri marketers Biogen Idec and Elan pulled it in February 2005 after two patients developed progressive multifocal leukoencephalopathy, or PML, a rare and often fatal brain infection. A third patient was later discovered to have PML. Two of the three patients died. In two of the cases, patients were also taking another Biogen drug, Avonex, at the same time, which led to speculation that Tysabri use alone might be less risky. “It is unclear for which patients the risk-benefit profile would be acceptable,” FDA staff said in a report released ahead of the advisory panel review, according to Reuters. The panel will also discuss a risk-management program that the companies have proposed should regulators sanction a return.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Researchers hit links for charity

The PMR Charities Golf Classic teed up more than $20,000 for St. Jude Children's Research Hospital.

FDA to review Neupogen biosimilar

Novartis subsidiary Sandoz announced Thursday that the FDA has agreed to review its filgrastim biosimilar which is already approved in 40 countries.

FDA approves a new painkiller

Targiniq ER combines the prescription opioid oxycodone and naloxone, which is often used to treat overdoses.